These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6768163)

  • 21. Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.
    Ofosu FA; Modi GJ; Blajchman MA; Buchanan MR; Johnson EA
    Biochem J; 1987 Dec; 248(3):889-96. PubMed ID: 2963622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of the early stages of the thrombin generation reaction by various glycosaminoglycans.
    Visser A; Meuleman DG
    Thromb Res; 1990 Jun; 58(5):469-79. PubMed ID: 2164263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of acetaldehyde-glycosaminoglycan mixtures upon Factor IXa and Factor IX-Deficient Plasma.
    Brecher AS; Moon AR; Gray KD
    Alcohol; 2006 Jun; 39(2):97-104. PubMed ID: 17134662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of various glycosaminoglycans upon cAMP-dependent protein kinase.
    Dittmann J; Krischek C; Harisch G
    Cell Biochem Funct; 1999 Mar; 17(1):21-8. PubMed ID: 10191505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The anticoagulant properties of mast cell product, chondroitin sulphate E.
    Scully MF; Ellis V; Seno N; Kakkar VV
    Biochem Biophys Res Commun; 1986 May; 137(1):15-22. PubMed ID: 3087353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of proteoglycans (PG) and glycosaminoglycans (GAG) on ADP-, collagen- and thrombin-induced platelet aggregation.
    Klein K; Sinzinger H; Silberbauer K; Stachelberger H; Leithner C
    Artery; 1980; 8(5):410-5. PubMed ID: 6783013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans.
    Cosmi B; Cini M; Legnani C; Pancani C; Calanni F; Coccheri S
    Thromb Res; 2003 Mar; 109(5-6):333-9. PubMed ID: 12818259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
    Nurmohamed MT; Fareed J; Hoppensteadt D; Walenga JM; ten Cate JW
    Semin Thromb Hemost; 1991; 17 Suppl 2():205-13. PubMed ID: 1948091
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation.
    Hollenstein UM; Pernerstorfer T; Homoncik M; Hansen JB; Finzen H; Handler S; Jilma B
    J Infect Dis; 2002 Nov; 186(9):1270-6. PubMed ID: 12402196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Argatroban, a new treatment option for heparin-induced thrombocytopenia.
    Cleveland KW
    Crit Care Nurse; 2003 Dec; 23(6):61-6. PubMed ID: 14692173
    [No Abstract]   [Full Text] [Related]  

  • 31. [New antithrombotic drugs (excluding plasminogen activators].
    Lecompte T
    Arch Mal Coeur Vaiss; 2001 Nov; 94(11 Suppl):1225-32. PubMed ID: 11794963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Demonstration of a direct anti-factor Xa activity in certain heparin-related glycosaminoglycans.
    Larsson A; Fransson LA; Lewis WE
    Thromb Res; 1982 Jun; 26(6):401-9. PubMed ID: 7112518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.
    Zammit A; Dawes J
    Thromb Haemost; 1994 Jun; 71(6):759-67. PubMed ID: 7526481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of glycosaminoglycans on thrombin- and atroxin-induced fibrin assembly and structure.
    Carr ME; Powers PL
    Thromb Haemost; 1989 Dec; 62(4):1057-61. PubMed ID: 2559486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of glycosaminoglycans on the growth of cultured tumor cells.
    Nagasawa S
    J Osaka Dent Univ; 1993 Oct; 27(2):121-33. PubMed ID: 8182504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of acidic glycosaminoglycans in human aortic inner and outer layers on partial thromboplastin time.
    Murata K; Izuka K; Nakazawa K
    Atherosclerosis; 1978 Jan; 29(1):95-104. PubMed ID: 629829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans in rabbits.
    Fernandez FA; Buchanan MR; Hirsh J; Fenton JW; Ofosu FA
    Thromb Haemost; 1987 Jun; 57(3):286-93. PubMed ID: 3116701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombin-mediated activation of endogenous factor XI in plasma in the presence of physiological glycosaminoglycans occurs only with high concentrations of thrombin.
    Wuillemin WA; Mertens K; ten Cate H; Hack CE
    Br J Haematol; 1996 Feb; 92(2):466-72. PubMed ID: 8603018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The in vitro anticoagulant effects of danaparoid, fondaparinux, and lepirudin in children compared to adults.
    Ignjatovic V; Summerhayes R; Yip YY; Monagle P
    Thromb Res; 2008; 122(5):709-14. PubMed ID: 18384841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of glycosaminoglycans on coagulation: a thromboelastographic study.
    Senzolo M; Coppell J; Cholongitas E; Riddell A; Triantos CK; Perry D; Burroughs AK
    Blood Coagul Fibrinolysis; 2007 Apr; 18(3):227-36. PubMed ID: 17413758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.